Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (November 2021)
81 slides from Coloplast A/s Class B's roadshow presentation, November 2021
Slide 1: Roadshow presentation FY 2020/21
Roadshow presentation FY 2020/21 Making life easier Kristian, IC device user STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid FY 2020/21 results with organic growth of 7% and 33% EBIT margin
Solid FY 2020/21 results with organic growth of 7% and 33% EBIT margin1) despite a challenging year due to COVID-19 REVENUE GROWTH FY 2020/21 Highlights Reported revenue (mDKK) +5% • Organic growth of 7% and reported growth in DKK of 5% (10% organic growth in Q4) Organic growth • Organic growth by b
Slide 4: Solid progress on Strive25 strategy – Sustainable Growth Leadership
Solid progress on Strive25 strategy – Sustainable Growth Leadership Growth Innovation . US Chronic Care Chronic Care – Clinical Performance Programme - Expanded the Ostomy Care sales force to capitalise on the GPO access - Initiated payer pilot studies on the Digital Ostomy Tool in Germany and the U
Slide 5: FY 2020/21 growth was broad-based across business areas and geographies
FY 2020/21 growth was broad-based, driven by the resumption of hospital activity across business areas and geographies FY 20/21 revenue by business area FY 20/21 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic growth Share of o
Slide 6: Ostomy Care grew 10% in Q4
Ostomy Care grew 10% in Q4, driven by continued improvement in Europe, and Emerging markets. FY 2020/21 organic growth was 6% Ostomy Care performance Q4 and FY 2020/21 Highlights • Q4 organic growth was 10% and reported growth was 12% 12 • Europe was positively impacted by an improved underlying gro
Slide 7: Continence Care grew 8% in Q4
Continence Care grew 8% in Q4 driven by improved underlying growth in Europe. FY 2020/21 organic growth was 5% Continence Care performance Q4 and FY 2020/21 Highlights • Q4 organic growth was 8% and reported growth was 9% • Europe, led by France and the UK, were the main growth contributors to growt
Slide 8: Interventional Urology grew 10% in Q4
Interventional Urology grew 10% in Q4 driven by US Men’s Health and a lower baseline. FY 2020/21 organic growth was 19% Interventional Urology performance Q4 and FY 2020/21 Highlights • Q4 organic growth was 10% and reported growth was 9% 82 • Positive impact from the continued recovery in elective
Slide 9: Wound & Skin Care grew 15% in Q4
Wound & Skin Care grew 15% in Q4. FY 2020/21 organic growth for WSC was 8% and 11% for WC driven by Europe and China Wound & Skin Care performance Q4 and FY 2020/21 Highlights • Q4 organic growth was 15%, reported growth was also 15% 20 • Wound Care in isolation grew 12% driven by EM, in particular
Slide 10: FY 2020/21 reported revenue was up 5%
FY 2020/21 reported revenue was up 5%, impacted by the depreciation of the USD and Emerging market currencies FY 2020/21 Revenue development (DKKm) FY 2020/21 Highlights • Reported revenue increased by DKK 882 million. Organic growth was 7% or DKK 1,308 million 1,308 23 -450 • Main drivers of perfor
Slide 11: FY 2020/21 reported EBIT margin of 33%
FY 2020/21 reported EBIT margin of 33%1) driven by efficiency gains and lower commercial spending due to COVID-19 FY 2020/21 EBIT margin development (%) FY 2020/21 Highlights • Gross margin was 69% compared to 68% last year 33.2 • Positive impact from leverage on production costs and 0.2 -0.1 0.1 32
Slide 12: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments FY 2020/21 Highlights • Free cash flow was DKK 3,279 million compared to DKK 3,858 million in FY 2019/20 98 99 98 93 93 • Adjusting for the acquisition of Nine Continents Medical, the free 90 cash flow for FY 2020/21 was
Slide 13: Organic growth guidance for FY 2021/22
Organic growth guidance for FY 2021/22, excluding impact from the Atos Medical acquisition GUIDANCE 2021/22 GUIDANCE 2021/22 (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalized g
Slide 14: Introduction to Coloplast
Making it easier Stina to be yourself LEADING INTIMATE HEALTHCARE Introduction to Coloplast
Slide 15: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2020/21 by segment Group revenue 2020/21 by geography 1 Continence Care European 1 36% markets 58% Ostomy Care Other developed 40% markets DKK DKK 25% 19.4bn 19.4bn 4 5 Interventional Urology Emerging Wound & Skin Care 11
Slide 16: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs WHO ARE OUR TYPICAL USERS HOW DO WE HELP THEM? People who have had their intestine redirected to an SenSura® Mio Ostomy Care opening in the abdominal wall Ostomy bag People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 17: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 18: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 19: Strong market positions in Europe and great commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Interventional Urology Wound Care Emerging Addressable market 18 - 19bn 14 - 15bn 12 - 13bn 22 - 24bn Size in DKK 4 - 5% 5 - 6% 3 - 5% 2 - 4% Growth in %* Coloplast
Slide 20: We are building the consumer healthcare company of the future
We are building the consumer healthcare company of the future MACRO TRENDS IMPACT COMMERCIAL MODEL Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Payer preferen
Slide 21: Our Strive25 strategy will drive continued long-term value creation
Our Strive25 strategy will drive continued long-term value creation through revenue and earnings growth Chronic Care Interventional Wound & Urology Skin Care 7-9% more than30% organic growth p.a. EBIT margin1 Talent, Innovation Leadership & Culture Unparalleled Sustainability efficiency 1) Constant
Slide 22: Supporting sustainable development with emphasis on environmental performance
Supporting sustainable development with a strong emphasis on improving our environmental performance Our mission Making life easier for people with intimate healthcare needs Stina Our 2025 priority Our 2025 priority Improving Reducing products and emissions packaging 90% of packaging is recyclable N
Slide 23: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue Key Investment Decision Drivers Key Investment Areas Economics & We expect to invest up to 2% Innovation of revenue in incremental OPEX investments Government Market Chronic Care Attractiveness U
Slide 24: We will actively pursue M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic screening based Portfolio Channel Early stage Large plays expansion & expansion technologies adjacencies Page 24
Slide 25: Key enablers to support the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses COMMERCIAL MODEL KEY ENABLERS Direct Businesses Superior, clinically differentiated products Coloplast Consumer Care Consumer Clinical preference Data and digital tools preference Direct to Consumer Payer prefe
Slide 26: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Care presence Control and continuity of 1 product supply ~30% MS ~15% MS ~5% MS +30 countries 2 Target the full value p
Slide 27: Clinical Performance Program to tackle the biggest issues users face
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? of users describe UTIs are their 45 %* 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 28: Significant progress across the Clinical Performance Program
We made significant progress across the Clinical Performance Program during 2020/21 Status October 2020 Status September 2021 Expected launch Product launch Digital ostomy - CE mark has been granted expected in first solution Pilot studies conducted with successful results ✓ - Payer pilot studies in
Slide 29: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, % Cost item Development, in % of revenue +0.1%-points 28.1 28.7 29.0 28.7 28.2 28-30 Distribution +0.4%-points 68.1 67.3 67.7 68.0 68.5 ~68 -0.1%-points 4.0
Slide 30: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE 9% ~800 >1,000 DKK ~450m # of FTE release ~500 CAPEX investment over ~200 through automation four years (19/20 – 22/23) Salary1 (Direct labour) 19/20 20/21 21
Slide 31: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / accounting Master Data Labelling (Chronic
Slide 32: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Future drivers of EBIT margin ILLUSTRATIVE EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and >30% R&D costs especially dri
Slide 33: Continued strong development in free cash flow
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX(2) Reported tax rate Net working capital, % of revenue CAPEX DKKm CAPEX, % of revenue Depreciation, % of revenue 5% 6% 5% 4% 4% 4% 5% 4% 4% 4% 4% ~24% 4% 1,016 23% 23% 23% 23% 23% ~2
Slide 34: Attractive cash returns despite large investments
We will continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Highlights Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liquidity to share
Slide 35: Coloplast can continue to deliver stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 33% • Stable market trends in our Chronic Care business 10% 7% • Strong Coloplast Care retention program 9% and innovative DtC activities 06/07 08/09 10/1
Slide 36: Appendices
Tabitha Leading intimate healthcare LEADING INTIMATE HEALTHCARE Appendices
Slide 37: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Coloplast share listed on Nasdaq Copenhagen since 1983 Share Capital Ownership ~223 billion DKK (~35 billion USD) market cap @ ~1,049 DKK 11% per share (incl. A shares) 5% 1% Two share classes: 45% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (f
Slide 38: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a 0.3x combination of dividends and share buy- 0.1x 0.1x 0.1x 0.2x backs • Interest bearing debt will only be raised in connection with a major acquisition or other spec
Slide 39: Q4 growth driven by Chronic Care in Europe and Emerging Markets
Q4 growth was driven by continued improvement in growth momentum in Chronic Care in Europe and Emerging Markets Q4 20/21 revenue by business area Q4 20/21 revenue by geography Business Reported revenue Q4 Organic growth Share of organic Geographic Reported revenue Q4 Organic growth Share of area DKK
Slide 40: Q4 reported growth was up 11%
Q4 reported growth was up 11%, 1%-point above organic growth due to positive impact from currencies, mainly GBP and CNY Revenue development (DKKm) Q4 Highlights • Reported revenue increased by DKK 510 million, or 11% compared to Q4 2019/20 • Q4 organic growth was 10% or DKK 468 million 468 11 31 5,1
Slide 41: Reported EBIT margin of 32% in Q4
Reported EBIT margin of 32% in Q4 reflecting efficiency gains, partly offset by commercial investments and normalization of activities EBIT margin development (%) Q4 Highlights • Q4 gross margin was 69%, on par with Q4 last year 0.4 32.8 • Positive impact from leverage and Global Operations Plans 4
Slide 42: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 32.7 36.3 36.2 36.8 31.9 32.3 34.7 34.6 32.0 31.5 28.7 29.0 28.1 28.7 28.2 25.2 23.4 23.6 23.4 23.7 4.0 4.0 4.2 4.1 3.9 4.4 5.0 5.2 4.1 3.5 3.7 3.9 3.9 3.8 3.9 16/17 17/18 18/19 19/20 20/21 16/17 17/18 18/19 19/20 20/21 Admin-to-Sales (%)
Slide 43: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 7 9 8 6 6 19 6 7 13 5 4 10 10 14 6 7,841 6 8 9 7,166 7,538 10 10 6,291 6,643 7 5 6 -7 1,641 1,740 1,970 1,835 2,097 16/17 17/18 18/19 19/20 20/21 16/17 17/18 18/19 19/20 20/21 Continence Care Wound & Skin Care 7 8 9 6
Slide 44: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 5 6 6 2 4 15 16 2 5 6 2 11 4 8 11 8 4 5 10,573 10,820 11,261 6 9,394 9,941 3 3,791 4,380 4,644 4,785 3,642 16/17 17/18 18/19 19/20 20/21 16/17(1) 17/18 18/19 19/20 20/21 Emerging Markets Coloplast group 7 8 9 4 7 14
Slide 45: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 57 60 60 59 57 2,193 2,200 2,156 2,225 2,011 41 46 43 37 31 42 42 42 40 39 252 269 269 244 238 239 199 214 200 160 Q4 19/20 Q1 20/21 Q2 20/21 Q3 20/21 Q4 20
Slide 46: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2020/21 and hedging policy Revenue FX exposure 2021/22(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -420 USD -170 EUR 36% -290 CNY, JPY, AUD, BRL & ARS 13% GBP -200 HUF 0 120 14% GBP 19% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 47: US Mesh litigation – Overview of financial impact
US Mesh litigation – Overview of financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 5,854 6,355 Special items -1,000 -3,000 - 750
Slide 48: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC Reimbursement pressure Page 48
Slide 49: CARE helps increase retention and improve product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 50: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 50
Slide 51: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance $ Product Page 51
Slide 52: Interventional Urology's revenue is balanced
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 13-14bn market FY 20/21 growing 3-5% annually 11% Coloplast position, FY 20/21 Endourology Men’s Health Women’s Health Bladder H
Slide 53: Select products
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S BLADDER HEALTH & ENDOUROLOGY HEALTH HEALTH SURGERY • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 54: Strong presence in categories with room to capture share
We have a strong presence in our categories but there is room to capture market share Coloplast Share Competitive Share Men’s Health Women’s Health Endourology1 Bladder Health & Surgery1 <5% 30-35% <5% 35-45% 35-45% 10-15% 15-20% Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) in
Slide 55: Coloplast acquires Nine Continents Medical
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 56: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn RoW Silic
Slide 57: The Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 58: In US Ostomy Care, innovation is the biggest growth driver
In US Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway We have gained significant share over the last Innovation is a key driver, and we will continue to expand our offering years of high-quality products Bags & Plates acute share SenSura® Mio portfo
Slide 59: Awarded access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute Estimated Contract start Contract Contract members1 Acute share2 date length type 3,6
Slide 60: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products and packaging Reducing emissions Responsible operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products As a growing company, we are challenged Our people and cult
Slide 61: FY 2020/21 progress on key sustainability ambitions
FY 2020/21 progress on key sustainability ambitions1) Improving products and packaging Reducing emissions Responsible operations 2025 FY FY 2025 FY FY 2025 FY FY Ambition 20/21 19/20 Ambition2) 20/21 19/20 Ambition 20/21 19/20 Renewable 80% 70% 70% Scope 1+2 23,100 21,000 White-collars 100% 99% 98%
Slide 62: Our 2025 priority: Reducing emissions
Our 2025 priority: Reducing emissions We are committed to reducing emissions while being a growth company Scope 3 - Other reported Scope 1 & 2 - Natural gas 2025 target – Scope 1+2 9% and company cars 13% Net-zero 100% Renewable energy (PPAs and phase out Scope 3 – Transportation natural gas use) of
Slide 63: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 64: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products • Market size of DKK ~3bn • Market growth of 6-8% • Market share 35-40% Brava® Protective Seal Brava® Skin Barrier • Main competitors include: Hollister • Designed for leakage • Reducing skin problems Adapt, ConvaTec, 3M Ca
Slide 65: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia (BPH) & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Oth
Slide 66: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Peristeen® Plus Anal Irrigation Faecal incontinence Launched in 2021 + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many •
Slide 67: Introducing Interventional Urology
Introducing Interventional Urology Surgical treatment of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Custo
Slide 68: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Customer groups Wound Care other Contract manufacturing & call points Hospitals Biatain® Silicone Non-Border B
Slide 69: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 70: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 71: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology R&D Marketing Sales R&D Marketing Marketing Operations Sales Regions Global Operations Global Business Support F
Slide 72: Coloplast Executive Leadership Team
Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Camilla G. Møhl Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 1972
Slide 73: Income statement
Income statement DKKm FY 2019/20 FY 2020/21 Change Revenue 18,544 19,426 5% Gross profit 12,612 13,313 6% SG&A costs -6,079 -6,247 3% R&D costs -708 -755 7% Other operating income/expenses 29 44 52% Operating profit (EBIT) before special items 5,854 6,355 9% Special items - -200 Operating profit (EB
Slide 74: Balance sheet
Balance sheet DKKm 30 Sep 2020 30 Sep 2021 Change Balance, total 13,499 15,841 17% Assets Non-current assets 7,010 8,847 26% Current assets 6,489 6,994 8% of which: Inventories 2,227 2,428 9% Trade receivables 2,934 3,212 9% Marketable securities, cash, and cash equivalents 585 674 15% Equity and li
Slide 75: Cash flow
Cash flow DKKm FY 2019/20 FY 2020/21 Change EBIT 5,854 6,155 5% Depreciation and amortisation 851 792 -7% Change in working capital -352 -75 -79% Net interest payments -182 -50 -73% Paid tax -1,277 -1,501 18% Other -135 -31 -77% Cash flow from operations 4,759 5,290 11% 1) Investment in intangibles
Slide 76: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 5% Hungary 12% 0% Mørdrup China 2% Tatabánya Minneapolis Nyirbátor Sarlat US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 81% COGS by cost type² 9% 18% Salary - Direct 12% Salary - Indirect 7% Materials (RM &SFG) Innovation & Specialised Pro
Slide 77: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,800 T
Slide 78: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Sarlat Mankato • Disposable surgica
Slide 79: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 80: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Aleksandra Dimovska Hannah Katrine Larsen Otto Munk Madsen Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Student Assistant, Investor Relations Tel. direct: +45 49
Slide 81: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /